Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Performance of Prenatal Cell-free DNA Screening in the Identification of Sex Chromosome Abnormalities: Experience of a Commercial Laboratory

ASHG 2025

American Society of Human Genetics

Boston, MA, Oct 14-18, 2025

Oral presentation: Performance of Prenatal Cell-free DNA Screening in the Identification of Sex Chromosome Abnormalities: Experience of a Commercial Laboratory

Pg. 3458

Authors: Blazejewski L, Niemchak T

Medical Specialty: Genetics, Women's Reproductive Health

Related content

Audio Podcast
Insights into successful family planning: A diagnostics perspective
By: Damian “Pat” Alagia, III, MD, MS, MBA, FACS, FACOG
Conference Presentation
Maternal Sex Chromosome Aneuploidy and CNVs as an Explanation for Non-Reportable Aneuploidy and Microdeletion Results on Fetal Cell-Free DNA Screening
Conference Presentation
The Proportion of Reportable cfDNA Screening Results for Fetal Aneuploidy in Pregnancies Less Than 10 Weeks Gestation
Test FAQ
QNatal Advanced
Publication
Fine Particulate Matter Exposure and Sperm DNA Fragmentation in US Men: A Spatial Cross-Sectional Study
Test FAQ
Ovarian Assessment Report (OAR)

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.